Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media

Iino, Yukiko; Takahashi, Eri; Ida, Saeko; Kikuchi, Saori

doi:10.1016/j.anl.2018.07.011

Cited by 29 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Authors [31] demonstrated that after anti-IgE treatment, not only asthma, but also hearing loss improved and bone conduction hearing was stable for an extended period with anti-IgE monoclonal antibodies. Literature data demonstrated that anti-IL-5 monoclonal antibodies may improve not only symptoms, but also the QoL of severe asthma, ECRS, and EOM [32,33]. Nevertheless, efficacy of treatments was quite limited in patients with the most refractory and resistant form of EOM, and especially in the granulation type, in which the mechanism responsible for highly granulated mucosa has not been determined yet [12].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP

Corso

Montuori

Settimi

et al. 2022

JCM

View full text Add to dashboard Cite

Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media characterized by eosinophilic accumulation in the middle ear mucosa and effusion. It is resistant to conventional treatments and strongly associated with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of our study is to evaluate the effectiveness of biologics drugs in the control of EOM. This is a retrospective no-profit real-life observational study, involving patients affected by refractory EOM and in treatment with different biologics for concomitant severe eosinophilic asthma or severe uncontrolled CRSwNP (Dupilumab: n = 5; Omalizumab: n = 1; Mepolizumab: n = 1; Benralizumab: n = 1). We analyzed data at baseline and at the 6-month follow-up, including specific nasal and otological parameters. We observed an improvement of all nasal outcomes, including NPS, SNOT-22, VAS, and smell function. Regarding specific otological parameters, we observed a significant reduction in the mean value of COMOT-15 score and of Otitis Severity Score at 6-month follow-up compared to baseline (p < 0.05). Finally, we observed an improvement in terms of air conduction hearing levels during the treatment. Our results demonstrated that anti type-2 inflammatory pathway biologics can be effective in improving symptoms control and in reducing the severity of eosinophilic otitis media when treating coexisting type-2 diseases, such as asthma and or CRSwNP.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP

Corso

Montuori

Settimi

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Mepolizumab, a humanized anti-IL-5 monoclonal antibody, is used for patients with moderate-to-severe bronchial asthma. In a retrospective study of patients with EOM associated with bronchial asthma who were treated with mepolizumab, anti-IL-5 therapy was highly effective in relieving EOM symptoms [ 18 ]. Our group demonstrated the expression of TSLP in an animal model of EOM [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

CD11c(+) dendritic cells coexpressing thymic stromal lymphopoietin receptor in animal model of eosinophilic otitis media

Hara

Kudo

Suzuki

et al. 2020

Asia Pacific Allergy

View full text Add to dashboard Cite

Background: Eosinophilic otitis media (EOM) is an intractable middle ear disease often associated with eosinophilic inflammatory airway conditions. Recently, dendritic cells (DCs) have been indicated as an essential component of Th2 allergic inflammation, such as bronchial asthma. DCs are activated by thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. However, the relationship between TSLP and DCs in EOM remains unknown. Objective: This study aimed to investigate the relationship between DCs and TSLP and to determine the involvement of DCs in EOM in an animal model. Methods: Hartley guinea pigs were used as the animal model. Daily ovalbumin (OVA) stimulation of the middle ear was performed for 7 or 14 days. The temporal bone was dissected on the last day of stimulation, and paraffin-embedded sections were prepared. Immunostaining and immunofluorostaining for TSLP receptor (TSLPR) and CD11c, a surface marker of DCs, were performed. Results: We found CD11c-immunopositive cells in the submucosal area of the middle ear epithelium, particularly around the eustachian tube. TSLPR-immunopositive cells exhibited a similar distribution as CD11c-positive cells. Conclusion: CD11c positive DCs coexpressing TSLPR were recruited after OVA challenge which might activate Th2 allergic reaction.

show abstract

“…The medical significance of mAb therapies and the highly developed and specialized purification technology provide a fertile ground for techno-economic feasibility analysis of an in situ resource utilization (ISRU)-based pharmaceutical foundry for space. The first reason is that there are mAb therapies commercially approved or in development for multiple important disease states of spaceflight including osteoporosis ( Faienza et al, 2018 ), migraines/headaches ( Schuster and Rapoport, 2016 ), seizure ( Zhao et al, 2017 ), pneumonia ( Hua et al, 2014 ), ocular herpes ( Krawczyk et al, 2015 ), otitis media ( Iino et al, 2019 ), various oncological indications ( Zahavi and Weiner, 2020 ), and fungal infections ( Ulrich and Ebel, 2020 ). A second reason is that degradation products of mAb therapies are known to result in, not just reduced efficacy, but also deleterious effects (e.g., harmful immune reactions in patients) that further compound concerns of pharmaceutical stability over a long-duration mission ( Laptoš and Omersel, 2018 ).…”

Section: Methodsmentioning

confidence: 99%

Evaluating the Cost of Pharmaceutical Purification for a Long-Duration Space Exploration Medical Foundry

et al. 2021

View full text Add to dashboard Cite

There are medical treatment vulnerabilities in longer-duration space missions present in the current International Space Station crew health care system with risks, arising from spaceflight-accelerated pharmaceutical degradation and resupply lag times. Bioregenerative life support systems may be a way to close this risk gap by leveraging in situ resource utilization (ISRU) to perform pharmaceutical synthesis and purification. Recent literature has begun to consider biological ISRU using microbes and plants as the basis for pharmaceutical life support technologies. However, there has not yet been a rigorous analysis of the processing and quality systems required to implement biologically produced pharmaceuticals for human medical treatment. In this work, we use the equivalent system mass (ESM) metric to evaluate pharmaceutical purification processing strategies for longer-duration space exploration missions. Monoclonal antibodies, representing a diverse therapeutic platform capable of treating multiple space-relevant disease states, were selected as the target products for this analysis. We investigate the ESM resource costs (mass, volume, power, cooling, and crew time) of an affinity-based capture step for monoclonal antibody purification as a test case within a manned Mars mission architecture. We compare six technologies (three biotic capture methods and three abiotic capture methods), optimize scheduling to minimize ESM for each technology, and perform scenario analysis to consider a range of input stream compositions and pharmaceutical demand. We also compare the base case ESM to scenarios of alternative mission configuration, equipment models, and technology reusability. Throughout the analyses, we identify key areas for development of pharmaceutical life support technology and improvement of the ESM framework for assessment of bioregenerative life support technologies.

show abstract

Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media

Cited by 29 publications

References 20 publications

Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP

Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP

CD11c(+) dendritic cells coexpressing thymic stromal lymphopoietin receptor in animal model of eosinophilic otitis media

Evaluating the Cost of Pharmaceutical Purification for a Long-Duration Space Exploration Medical Foundry

Contact Info

Product

Resources

About